9.3.2 Toxicities: 
In general, adverse reactions to mesna have been mild and readily 
managed including headaches, arthralgia and diarrhea. Hypotension 
and allergy were reported in 1/6 patients on phase I study. 
10.0 PATIENT ELIGIBILITY 
10.1 Patients with acute nonlymphocytic leukemia in first remission are eligible for 
this protocol. 
10.2 Patient exclusion includes patients with: 
1. HLA-matched, MLC-compatible donor (unless parents and/or patient 
refuses allogeneic transplant) 
2. Previous allogeneic transplant or autologous transplant 
3. life expectancy limited by disease other than leukemia 
4. significant cardiac disease 
5. severe renal dysfunction, i.e., creatinine clearance less than 60 cc/1.73 
m^ 
6. severe restrictive pulmonary disease (FVC less than 40% of predicted) 
7. severe hepatic disease (bilirubin greater than 3 mg/dl or SGPT greater 
than 500 lU) 
8. severe personality disorder or mental illness 
9. previous severe cystitis from cyclophosphamide 
10. previous total dose of anthracyclines of >450 mg/m^ 
11. severe infection that on evaluation by the Principal Investigator 
precludes ablative chemotherapy or successful transplantation 
12. HIV reactivity 
13. Kamofsky score <70%. 
14 Acute Promyelocytic Leukemia 
11. OUTLINE OF THERAPY 
Harvest guidelines: 
Patients will enter the study at the time of bone marrow harvest. Bone marrow must 
be obtained and frozen during a complete remission. Transduction will be done 
before the cells are frozen and stored. It is anticipated that patients will have their 
bone marrow harvested and then proceed directly to conditioning and transplantation. 
However, there may be some patients who have their marrow stored for 
transplantation at a much later date. Criteria for marrow harvest must include: 
Recombinant DNA Research, Volume 14 
[523] 
